Novo Nordisk (NVO) is trading higher as investors react to a fresh U.S. FDA proposal that would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The 503B bulks list is the mechanism that determines which bulk drug substances FDA-registered outsourcing facilities can use to compound medicines under Section 503B of the FD&C Act. The FDA’s stated rationale is that it did not identify a clinical need for outsourcing facilities to compound these GLP-1 drugs from bulk substances, and it opened a public comment period that runs through June 29, 2026.

Semaglutide underpins Novo Nordisk’s obesity and diabetes blockbusters Wegovy and Ozempic. A stricter stance on large-scale compounding is broadly interpreted as a potential tailwind for branded demand by reducing the availability of compounded GLP-1 alternatives sold outside the originators’ commercial channels. While the proposal is not a final rule, it reinforces regulatory momentum that could limit the scale of 503B compounding activity tied to these molecules, which has been a persistent investor concern around pricing pressure, channel mix, and volume leakage in the U.S.

The FDA proposal now moves into a formal comment window through June 29, 2026, after which the agency will decide whether to finalize exclusions. Investors will also focus on Novo Nordisk’s next earnings report, scheduled for Wednesday, May 6, 2026, for updates on U.S. demand trends, realized pricing, and the competitive landscape in obesity care as the company heads deeper into 2026.